Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;26(9):1364-1374.
doi: 10.1038/s41591-020-1034-x. Epub 2020 Sep 9.

Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension

Collaborators, Affiliations
Review

Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension

Xiaoxuan Liu et al. Nat Med. 2020 Sep.

Abstract

The CONSORT 2010 statement provides minimum guidelines for reporting randomized trials. Its widespread use has been instrumental in ensuring transparency in the evaluation of new interventions. More recently, there has been a growing recognition that interventions involving artificial intelligence (AI) need to undergo rigorous, prospective evaluation to demonstrate impact on health outcomes. The CONSORT-AI (Consolidated Standards of Reporting Trials-Artificial Intelligence) extension is a new reporting guideline for clinical trials evaluating interventions with an AI component. It was developed in parallel with its companion statement for clinical trial protocols: SPIRIT-AI (Standard Protocol Items: Recommendations for Interventional Trials-Artificial Intelligence). Both guidelines were developed through a staged consensus process involving literature review and expert consultation to generate 29 candidate items, which were assessed by an international multi-stakeholder group in a two-stage Delphi survey (103 stakeholders), agreed upon in a two-day consensus meeting (31 stakeholders) and refined through a checklist pilot (34 participants). The CONSORT-AI extension includes 14 new items that were considered sufficiently important for AI interventions that they should be routinely reported in addition to the core CONSORT 2010 items. CONSORT-AI recommends that investigators provide clear descriptions of the AI intervention, including instructions and skills required for use, the setting in which the AI intervention is integrated, the handling of inputs and outputs of the AI intervention, the human-AI interaction and provision of an analysis of error cases. CONSORT-AI will help promote transparency and completeness in reporting clinical trials for AI interventions. It will assist editors and peer reviewers, as well as the general readership, to understand, interpret and critically appraise the quality of clinical trial design and risk of bias in the reported outcomes.

PubMed Disclaimer

Conflict of interest statement

M.J.C. has received personal fees from Astellas, Takeda, Merck, Daiichi Sankyo, Glaukos, GlaxoSmithKline and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. P.A.K. is a consultant for DeepMind Technologies, Roche, Novartis and Apellis, and has received speaker fees or travel support from Bayer, Allergan, Topcon and Heidelberg Engineering. C.J.K. is an employee of Google and owns Alphabet stock. A.E. is an employee of Salesforce CRM. R.S. is an employee of Pinpoint Science. J. Matcham was an employee of AstraZeneca at the time of this study. J. Monteiro is Chief Editor of the journal Nature Medicine; he has recused himself from any aspect of decision-making on this manuscript and played no part in the assignment of this manuscript to in-house editors or peer reviewers, and was also separated and blinded from the editorial process from submission inception to decision.

Figures

Fig. 1
Fig. 1. CONSORT 2010 flow diagram — adapted for AI clinical trials.
CONSORT-AI 4a (i): State the inclusion and exclusion criteria at the level of participants. CONSORT-AI 4a (ii): State the inclusion and exclusion criteria at the level of the input data. CONSORT 13b (core CONSORT item): For each group, losses and exclusions after randomization, together with reasons.

References

    1. Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? Br. Med. J. 1998;316:201. - PMC - PubMed
    1. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J. Clin. Epidemiol. 1995;48:23–40. - PubMed
    1. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. Br. Med. J. 2001;323:42–46. - PMC - PubMed
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J. Am. Med. Assoc. 1995;273:408–412. - PubMed
    1. Moher D, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Br. Med. J. 2010;340:c869. - PMC - PubMed

Publication types

MeSH terms